Esc peptides stabilize the opening of the CFTR channel and exhibit antibacterial activity against P. aeruginosa and S. aureus both in vitro and in vivo models
The chemical structure of inhibitors of the salicylate synthase enzyme from Mycobacterium abscessus has been identified to reduce the bacterium's virulence
The combined therapy of liposomes and amikacin is able to combat Mycobacterium abscessus infection and reduce inflammation in both in vitro and in vivo models
Enhancing the prediction of clinical responses to CFTR modulators by in vitro assays using patient-derived tissues under conditions mimicking native status of CF airways
Lead optimization of MKT-077 analogues as HSP70 allosteric inhibitors combined with F508del CFTR correctors: a multi-drug approach to contrast cystic fibrosis
Targeting small RNA-mediated regulation of virulence and antibiotic resistance to develop non-traditional therapeutic options against Pseudomonas aeruginosa
Tackling phage resistance to increase the robustness of phage therapy for curing Pseudomonas aeruginosa infections in patients with cystic fibrosis (PhaCyf)
Nanotechnology-based Resolvin D1 as Proresolving Therapy in Cystic Fibrosis: Preclinical Studies for the Delivery of Innovative Formulations to the Clinic
Intestinal organoids for assessment and pharmacological correction of abnormalities in fluid transport and anion currents in patients affected by pancreatitis
Establishment of Conditionally Reprogrammed Airway Epithelial Stem Cell cultures from nasal epithelia of Cystic Fibrosis patients: exploring response to CFTR-modulating drugs for correlation with genetic profile (theratyping) and restoring CFTR function through gene editing approaches
Targeting small RNA-mediated regulation of virulence and antibiotic resistance to develop non-traditional therapeutic options against Pseudomonas aeruginosa